Table 1:
Category | Variable | T | R | U | Variable | T | R | U | Variable | T | R | U |
---|---|---|---|---|---|---|---|---|---|---|---|---|
| ||||||||||||
Patient information | Demographics | • | • | • | Family & social history | • | • | Environmental exposure | • | |||
Presenting age | • | • | • | |||||||||
Tumor presentation | Tumor site | • | • | • | Tumor size | • | • | • | ||||
Histopathology | Tumor grade | • | • | • | ||||||||
Gene expression | VEGF | • | • | • | PTEN | • | • | • | MGMT | • | • | • |
EGFR VIII | • | • | • | TP53 | • | • | • | DNA methylation | • | • | • | |
Chemotherapy | Drug name | • | • | • | Frequency/dosage | • | • | • | Number of cycles | • | • | • |
Surgical resection | Type of procedure | • | • | • | Extent of resection | • | • | • | ||||
Radiation therapy | Type of radiation therapy | • | • | • | Fractionation | • | • | • | Total dosage | • | • | • |
Steroids | Drug name | • | • | • | Frequency | • | • | • | Dosage | • | • | • |
Other medications | Drug name | • | • | • | Frequency | • | • | • | Dosage | • | • | • |
Neurological assessment | Karnofsky score | • | • | • | Other | • | ||||||
Imaging assessment | Tumor volume | • | • | • | Non-contrast enhancing region | • | • | • | Mass effect | • | • | • |
Necrosis | • | • | • | Multi-focality | • | • | • | Satellites | • | • | • | |
Contrast enhancement | • | • | • | Edema volume | • | • | • | ADC map | • | |||
Outcomes | Time to progression (TTP) | • | • | • | Time to survival (TTS; death) | • | • | • |